Status:
COMPLETED
Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery
Lead Sponsor:
Mayo Clinic
Conditions:
Sellar and Suprasellar Masses
Pituitary Tumor
Eligibility:
All Genders
18-95 years
Brief Summary
1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin whic...
Detailed Description
Patient serum levels of copeptin would be measured after phlebotomy of 3 ml of blood in EDTA tube twice a) within 1-4 hours of extubation and b) within 4-24 hours of extubation (the morning following ...
Eligibility Criteria
Inclusion
- \* Patients with sellar and suprasellar masses who undergo neurosurgical procedure at Mayo Clinic Rochester.
Exclusion
- \* Patients with preexisting CDI.
Key Trial Info
Start Date :
January 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 29 2022
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT04369703
Start Date
January 28 2020
End Date
April 29 2022
Last Update
June 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55901